Matches in Nanopublications for { ?s ?p "[TMPRSS2-ERG, TMPRSS2-ETV1, and SLC45A3-ERG rearrangements account for roughly 90% of ETS fusion prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP378862.RAR54kYrn4k-KJHrLzA3Rlycn9VgS4IlEi2KkQDzoX93I130_assertion description "[TMPRSS2-ERG, TMPRSS2-ETV1, and SLC45A3-ERG rearrangements account for roughly 90% of ETS fusion prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP378862.RAR54kYrn4k-KJHrLzA3Rlycn9VgS4IlEi2KkQDzoX93I130_provenance.
- assertion description "[TMPRSS2-ERG, TMPRSS2-ETV1, and SLC45A3-ERG rearrangements account for roughly 90% of ETS fusion prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP191628.RA_s_dVDPymxYJmwyM5hELA9LElxCNUEPce9gg6VmbnjE130_assertion description "[TMPRSS2-ERG, TMPRSS2-ETV1, and SLC45A3-ERG rearrangements account for roughly 90% of ETS fusion prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP191628.RA_s_dVDPymxYJmwyM5hELA9LElxCNUEPce9gg6VmbnjE130_provenance.
- assertion description "[TMPRSS2-ERG, TMPRSS2-ETV1, and SLC45A3-ERG rearrangements account for roughly 90% of ETS fusion prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP726630.RAd4M53VSTo0t2Oqqk36HVI8ALirvqqYLcRQU8YLKLaZI130_assertion description "[TMPRSS2-ERG, TMPRSS2-ETV1, and SLC45A3-ERG rearrangements account for roughly 90% of ETS fusion prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP726630.RAd4M53VSTo0t2Oqqk36HVI8ALirvqqYLcRQU8YLKLaZI130_provenance.
- NP726633.RAZH8xkWizwkL4GTEohH4yS62GiJromIhaDUSBRGBTR5E130_assertion description "[TMPRSS2-ERG, TMPRSS2-ETV1, and SLC45A3-ERG rearrangements account for roughly 90% of ETS fusion prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP726633.RAZH8xkWizwkL4GTEohH4yS62GiJromIhaDUSBRGBTR5E130_provenance.
- NP726632.RAkbAnNsmJ4tvk-7ilTY-FEywqDnm3vI5w9Hoi-ffryHk130_assertion description "[TMPRSS2-ERG, TMPRSS2-ETV1, and SLC45A3-ERG rearrangements account for roughly 90% of ETS fusion prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP726632.RAkbAnNsmJ4tvk-7ilTY-FEywqDnm3vI5w9Hoi-ffryHk130_provenance.
- NP726636.RAsRcB644C7UKZkAGRBsCxgEuQ9J7InbV3YJJIDy0wVMI130_assertion description "[TMPRSS2-ERG, TMPRSS2-ETV1, and SLC45A3-ERG rearrangements account for roughly 90% of ETS fusion prostate cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP726636.RAsRcB644C7UKZkAGRBsCxgEuQ9J7InbV3YJJIDy0wVMI130_provenance.